Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Keefe, R. S.E. Articles by Lieberman, J. A. Search for Related Content PubMed Citation Articles by Keefe, R. S.E. Articles by Lieberman, J. A. Schizophrenia Spectrum Disorders Atypical Neuroleptics Cognition Related Article

Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison

OBJECTIVE: The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. METHOD: In a 52-week double-blind, multicenter study, 400 patients early in the course of psychotic illness (<5 years) were randomly assigned to treatment with olanzapine (2.5–20 mg/day), quetiapine (100–800 mg/day), or risperidone (0.5–4 mg/day). The mean modal daily dose was 11.7 mg (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone. A total of 224 patients completed neurocognitive assessments at baseline and at 12 weeks, and 81 patients also completed them at 52 weeks. Neurocognitive composite scores were calculated from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and from the Brief Assessment of Cognition in Schizophrenia. RESULTS: At week 12, there was significant improvement in neurocognition for each treatment (p<0.01), but no significant overall difference between treatments. Composite z score improvements on the CATIE neurocognitive battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone. Composite z score improvements on the Brief Assessment of Cognition in Schizophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidone. Statistically significant relationships between improvements in neurocognition and functional outcome were observed at weeks 12 and 52. CONCLUSIONS: Olanzapine, quetiapine, and risperidone all produced significant improvements in neurocognition in early-psychosis patients. Although cognitive improvements were modest, their clinical importance was suggested by relationships with improvements in functional outcome.

Related Article:

In This Issue
Am J Psychiatry 2007 164: A46. [Full Text] [PDF]

This article has been cited by other articles:

				Bibliography Schizophrenia Focus, January 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]

				N. Bergemann, P. Parzer, S. Jaggy, B. Auler, C. Mundt, and S. Maier-Braunleder Estrogen and Comprehension of Metaphoric Speech in Women Suffering From Schizophrenia: Results of a Double-Blind, Placebo-Controlled Trial Schizophr Bull, December 21, 2007; (2007) sbm138v1. [Abstract] [Full Text] [PDF]

				W. T. CARPENTER and R. R. CONLEY Challenge to Atypical Antipsychotic Drug Effect on Cognition Am J Psychiatry, December 1, 2007; 164(12): 1910 - 1911. [Full Text] [PDF]

				M. S. Kraus and R. S. E. Keefe Cognition as an outcome measure in schizophrenia The British Journal of Psychiatry, August 1, 2007; 191(50): s46 - s51. [Abstract] [Full Text] [PDF]

				R. S.E. Keefe, J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison Am J Psychiatry, July 1, 2007; 164(7): 1061 - 1071. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us